If the U.S. Supreme Court agrees to tackle the long-simmering question of whether so-called “pay-for-delay” deals between drug companies violate antitrust law, it’ll likely be up to Williams & Connolly’s Kannon Shanmugam to establish that the deals pass muster.
On August 24, Shanmugam filed a petition for certiorari for Merck & Co., asking the court to review a July decision by the U.S. Court of Appeals for the Third Circuit that revived antitrust claims over Merck’s potassium-chloride supplement K-Dur. Shanmugam was joined on the petition by lawyers from his firm, Covington & Burling, McCarter & English and Baker Botts.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
